Syndax’s Revumenib Makes Splash At ASH As Company Eyes Blockbuster Opportunity

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

The company presented data for the menin inhibitor in KMT2Ar acute leukemias in an ASH late-breaker. The larger addressable population, including mNPM1 AML, could be a $2bn opportunity.

• Source: Scrip

Syndax Pharmaceuticals, Inc. is starting out with a rare subset of acute leukemia patients when it submits revumenib for US Food and Drug Administration review at the end of the year, but it is also aiming for a larger subset that could potentially yield a blockbuster opportunity, one in which others hope to compete as well.

Key Takeaways

  • Syndax presented data from the pivotal Phase II AUGMENT-101 trial of revumenib in KMT2Ar acute myeloid leukemia and acute lymphoid leukemia at the ASH late-breaking abstract session.

The company presented results from the pivotal Phase II AUGMENT-101 trial in a late-breaking abstract at the American Society of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D